Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Head & Neck 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Colorectal Neoplasms 7Neoplasms 4Multiple Myeloma 4Hematologic Neoplasms 3Glioma 3Thyroid Carcinoma, Anaplastic 2Rectal Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Colonic Neoplasms 2Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Thrombocytosis 1Stomach Neoplasms 1Spinocerebellar Degenerations 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Nonseminomatous germ cell tumor 1Neoplasms by Site 1Neoplasms by Histologic Type 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Melanoma 1

Interventions

trametinib 1motexafin gadolinium 1dabrafenib 1Watchful Waiting 1Therapeutics 1Radiotherapy 1Radiation 1Psychiatric Rehabilitation 1Polymerase Chain Reaction 1PLX8394 1Microarray Analysis 1Ipilimumab 1Immunoenzyme Techniques 1Imatinib Mesylate 1Gene Expression Profiling 1Flow Cytometry 1Fentanyl 1Doxorubicin 1Dasatinib 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Hairy Cell × dabrafenib × Gastrointestinal × Clear all
NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Novartis

Phase 2 Completed
206 enrolled 40 charts 2 FDA
CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡